Abstract
Introduction
Renal complications are both a marker of previous suboptimal glycaemic control and a major risk factor for cardiovascular disease in persons with type 1 diabetes (T1D). The aim of the study was to evaluate the prevalence of renal complications in persons with T1D in four geographical regions.
Methods
Nationwide registry data from Austria/Germany, Sweden and the US were used to estimate the prevalence of renal complications from January 2016 until September 2018. Chronic kidney disease (CKD) and albuminuria in the study population and each registry were analysed by diabetes duration. Risk factors for renal complications were described by registry.
Results
In the total cohort of 78.926 adults with T1D, mean age was 44.4 ± 18.43 years and mean diabetes duration was 21.6 ± 22 years. Mean estimated glomerular filtration rate (eGFR) was 94.0 ± 31.45 ml/min, 13.0% had microalbuminuria and 3.9% had macroalbuminuria. Mean age, diabetes duration, use of insulin pumps and continuous glucose monitoring, as well as presence of albuminuria, varied between registries. Albuminuria was present in approximately 10% of persons with diabetes duration < 20 years and impaired renal function (eGFR < 60 ml/min) was present in 17%. In persons with diabetes duration > 40 years, approximately one-third had albuminuria and 25% had impaired renal function.
Conclusions
This analysis used three nationwide registries of persons with T1D. Despite recent use of more effective diabetes therapies, a substantial proportion of persons with T1D have renal complications at < 20 years after diagnosis. Efficient glucose-lowering and renal-protective strategies are needed in persons with T1D.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 NU Hospital Group, Department of Medicine, Trollhättan, Sweden (GRID:grid.459843.7) (ISNI:0000 0004 0624 0259); University of Gothenburg, Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)
2 University of Gothenburg, Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)
3 UNC Hospitals, Diabetes and Endocrinology Clinic at Meadowmont, Chapel Hill, USA (GRID:grid.429995.a)
4 International Diabetes Center, Minneapolis, USA (GRID:grid.417226.4) (ISNI:0000 0004 0434 2710)
5 Jaeb Center for Health Research, Tampa, USA (GRID:grid.414912.b) (ISNI:0000 0004 0586 473X)
6 ZIBMT, Ulm University, Institute for Epidemiology and Medical Biometry, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748); German Centre for Diabetes Research (DZD), Munich, Germany (GRID:grid.452622.5)
7 University Duisburg-Essen, Bochum, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445)
8 Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Diabetology, Graz, Austria (GRID:grid.11598.34) (ISNI:0000 0000 8988 2476)
9 Stanford University, Pediatric Endocrinology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)





